Nivolumab Alone Prevails in Resected Melanoma

(MedPage Today) -- Dual checkpoint blockade with nivolumab (Opdivo) plus ipilimumab (Yervoy) failed to improve outcomes as adjuvant therapy for resected melanoma over nivolumab alone, the CheckMate 915 trial found.
In the intent-to-treat (ITT...